Overview

* Nutex Health ( NUTX ) Q3 revenue grows 239.9% yr/yr, beating analyst expectations

* Net income for Q3 2025 at $55.4 mln, reversing loss from Q3 2024

* Company regains Nasdaq compliance following timely filing of reports

Outlook

* Company did not provide specific future guidance

Result Drivers

* HOSPITAL REVENUE - Hospital division revenue increased 262.8% driven by higher acuity claims and IDR process success

* ARBITRATION COSTS - Arbitration costs approximated 24-26% of arbitration-related revenue due to underpayment from payors

* STOCK-BASED COMPENSATION - Stock-based compensation expenses increased due to obligations for under-construction hospitals

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $267.8 $213.81

Revenue mln mln (3

Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* Wall Street's median 12-month price target for Nutex Health Inc ( NUTX ) is $220.00, about 54.9% above its November 18 closing price of $99.20

* The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 8 three months ago

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)